A new wave of TSHR targeting biotechs, anchored by Ethyreal's $101M Series A and B, is reframing thyroid eye disease and Graves' as a single autoimmune process.
While Amgen's Tepezza and Viridian's approaching FDA decision treat thyroid eye disease by blocking a downstream growth pathway, a cluster of biotechs is taking a different tack: hitting the upstream receptor that thyroid-stimulating autoantibodies actually activate. The field is bifurcating, and Ethyreal Bio's $101 million Series A and B, reported by Fierce Biotech on Wednesday, is the latest signal that the upstream play is attracting real capital.
The premise behind the bifurcation is clinical, not commercial. Thyroid eye disease and Graves' disease are autoimmune conditions that frequently co-occur in the same patient. The standard treatment course handles them in parallel: Tepezza for the eye, antithyroid drugs for the hyperthyroid thyroid, with neither addressing the shared TSHR autoantibody that drives both. The IGF-1R inhibitors in the TED pipeline, Amgen's Tepezza and Viridian's veligrotug, work downstream of the receptor, blocking a fibroblast signaling pathway that produces the orbital swelling, proptosis, and diplopia that define TED. They do not, however, touch the underlying autoantibody.
Ethyreal Bio, a Massachusetts-based biotech, is positioning its lead asset, an anti-TSHR antibody called ETHY-001, as the upstream alternative. The drug is preclinical, with a first-in-human trial scheduled to start in 2026, but the company has secured backing from Atlas Venture and Medicxi Ventures and a CEO in Niranjan Kameswaran, Ph.D., who framed the rationale in the Fierce Biotech write-up as a single antibody that could address both TED and Graves' by acting on the shared autoantibody driver.
The TSHR approach is not new, and the history is part of the story. Prior anti-TSHR antibody programs ran into problems with slow onset of action, immunogenicity, and, in some cases, induction of Graves' disease in patients treated for other conditions. Kameswaran's unmet-need framing, that current GD treatments do not prevent TED and current TED treatments do not address hyperthyroidism, is the constructive response to that history. Whether ETHY-001 clears the kinetic and immunogenicity bars that earlier programs did not is the open question, and the company has not yet presented preclinical data in a peer-reviewed forum.
The competitive structure around Ethyreal is a pack rather than a duel. Fierce Biotech identifies Yarrow and Ollin, a VelaVigo company, as peers also pursuing the TSHR mechanism. Viridian Therapeutics, by contrast, is the near-term benchmark on the IGF-1R side: its veligrotug has an FDA approval decision due this month, and the result will set the second-mover standard for the entire IGF-1R class. Amgen's Tepezza remains the on-market incumbent in TED.
The broader Graves' disease pipeline adds a second front. argenx is developing efgartigimod, Biohaven has BHV-1300, Immunovant has IMVT-1402, and Sanofi has rilzabrutinib. None of these is a direct TSHR antagonist, but several are FcRn or BTK inhibitors designed to reduce the pathogenic autoantibodies themselves. The GD pipeline is the second half of the same field reorg that the TED pipeline is now going through: a move from symptom control toward the upstream autoimmune process.
For Ethyreal, the next data checkpoint is the Endocrine Society 2026 Annual Meeting, where the company is expected to present preclinical work on ETHY-001. The 2026 first-in-human trial start, also flagged in the Fierce Biotech report, is the more durable milestone. Investors will read the FDA's veligrotug decision this month as a read-through to the entire TED space: a clean approval will harden the IGF-1R standard of care, a rejection or a label restriction will reopen it, and either outcome shapes the room ETHY-001 will walk into when its first clinical data lands.